Join us as we bring you the latest insights from ASCO 2026! In this episode, we dived deep into the groundbreaking RASolute-302 study, which has made waves in the treatment of metastatic pancreatic cancer. Discover how the novel RAS inhibitor, Daraxonrasib, has doubled overall survival rates from 6.7 months to an impressive 13.2 months for patients in the second-line setting.

Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

⁠X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

We were joined by esteemed experts Dr. Rachna Shroff, Dr. Shubham Pant, Dr. Eileen O'Reilly, and Dr. Andrew Ko, who shared their insights on the study's design, findings, and the implications for our clinical practice. We touched on the prevalence of RAS mutations in pancreatic cancer, the mechanism of action of Daraxonrasib, and the side effect profile that clinicians need to manage effectively.

Topics Covered:

Overview of the RASolute-302 study
Impact of Daraxonrasib on overall survival
RAS mutations in pancreatic cancer
Mechanism of action of RAS inhibitors
Side effects and management strategies

Tune in now for an enlightening discussion on the future of pancreatic cancer treatment!

#ASCO2026, #PancreaticCancer, #Daraxonrasib, #RASmutation, #OverallSurvival

RASolute-302 with Daraxonrasib - Game Changer at ASCO 2026 in Pancreatic Cancer

Oncology Brothers: Practice-Changing Cancer Discussions

RASolute-302 with Daraxonrasib - Game Changer at ASCO 2026 in Pancreatic Cancer